Frank Verheggen

Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies

Israel Franco, Piet Hoebeke, Małgorzata Baka‐Ostrowska et al. · Journal of Pediatric Urology · 2019 · 23 citations · Full text

Medicine, Pediatrics, Pharmacology +15

YM150, An Oral Direct Inhibitor of Factor Xa, Demonstrated a Predictable and Dose-Proportional Pharmacokinetic/Pharmacodynamic Profile After Single and Multiple Dosing: Results From Three Studies

Dorien Groenendaal‐van de Meent, Marten Heeringa, Takeshi Kadokura et al. · Blood · 2010 · 16 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans

Tadashi Hashimoto, Katsuhiro Suzuki, Yukie Kihara et al. · Xenobiotica · 2012 · 15 citations

Pharmacy, Pharmacokinetics, Pharmacology +8

Excretion and metabolism of desogestrel in healthy postmenopausal women

Carole Verhoeven, R.H.M. Gloudemans, Pauline Peeters et al. · The Journal of Steroid Biochemistry and Molecular Biology · 2001 · 13 citations · Full text

Medicine, Endocrinology, Pharmacology +4

Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects

Takeshi Kadokura, Makoto Kashiwa, Dorien Groenendaal et al. · Biopharmaceutics & Drug Disposition · 2013 · 12 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16